Heptares granted Shire an option to license a preclinical adenosine A2A receptor (ADORA2A) antagonist

Heptares Therapeutics Ltd.

U.K. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Shire plc

Ireland / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated